Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-365 in metastatic castration-resistant prostate cancer
2023-506987-15-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 21
01
Overview
Phase 2, open-label trial of pembrolizumab, vibostolimab + pembrolizumab, lenvatinib, olaparib, enzalutamide and 7 more in metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NEPC) (10 cohorts), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA), Number of Participants with Adverse Events (AEs) and 2 more. Planned start Nov 2016; status: authorised.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on 2023-506987-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506987-15-00.